Peptide Merchant Accounts for Research-Use-Only Sellers

Yes, knowingly and from the beginning. Research peptides, SARMs, and research chemicals sold for research use only are placed with acquiring relationships that board the category on purpose, and your actual site and catalog are reviewed before you go live. Underwriting reads the labeling, certificates of analysis, marketing copy, and dispute profile, rather than approving on a clean signup form and closing the account once a reviewer gets to the product line.

Yes. Most peptide applicants are at startup stage, and there is no minimum monthly volume, so a store that has not taken its first card payment can apply. With no statements to read, the review works from the storefront, the research-use-only labeling, the certificates of analysis, and the match between the bank account and the entity. A staging or preview link is enough to start if the site is not public yet.

Yes. Paste your site link, a staging or preview link is fine, and your catalog into the message field of the application, and you will hear whether the category and the setup fit before you commit to the build or incorporate. Your actual site and catalog are reviewed before you go live either way, so a pre-screen moves that read earlier. The answer is a fit-or-not read rather than a rate quote, because fees, any reserve, and the settlement timing come from the full review.

A peptide payment processor is the company that places and runs a peptide merchant account, together with the gateway behind checkout. For research-peptide, SARMs, and research-chemical sellers, mainstream processors are not built for the category, so the account and the gateway are placed together with an acquiring bank that reviews the research-use labeling and certificates of analysis before the first transaction.

Any platform, from WooCommerce to a custom build. The integration is handled for you or with your developer, and the gateway is chosen together with the account rather than bolted on afterward, with research-use disclaimers and age-gating configured in the checkout. Say which platform you run on the application, or that the site is not built yet, and the review starts on the setup that fits it.

A supplement account covers ingestible dietary products marketed for human consumption under DSHEA, often on subscriptions. A peptide account covers research compounds sold for research use only, with no human-use claims and an FDA-drug gray area. The underwriting and compliance review are different, so the two are kept on separate accounts.

Yes, directly. Marketing that describes dosing, injection, or human use moves the product from research use into unapproved-drug territory, which is the exact line FDA warning letters target. Keeping the site, labels, and disclaimers strictly research-use-only is part of staying approved, and that copy is reviewed during underwriting.

The catalog is part of the site review, so list what you sell in the application and name any GLP-1 analog such as tirzepatide or retatrutide explicitly rather than burying it. There is no published list of approved compounds, and a merchant account is never a judgment that a product is legal to sell. The review prices the payment risk of the labeling, the claims, and the dispute profile, and the legality of the catalog stays with you and your counsel.

Certificates of analysis for the compounds sold are expected during review. They show product identity and purity and support the research-use framing, which helps underwriting separate a documented research-supply business from an unlabeled research-chemical seller making health claims.

A voided check or bank letter for the deposit account, formation documents, the IRS EIN confirmation letter (CP-575 or 147C), recent business bank statements even for a brand-new account (a bank letter stands in only where the review accepts one), and photo ID for each owner with 25% or more ownership, followed by the merchant application itself. Peptide sellers add research-use-only labeling, certificates of analysis for the compounds sold, and site copy free of human-consumption or dosing claims. Our application itself asks for no documents; the list is shown again on the screen after you apply, and the merchant application email requests them.

Yes. A prior shutdown is common for research-peptide sellers, because mainstream platforms often board first and review later, and the category can surface at the first review or dispute. Underwriting reads your transaction profile, product line, labeling, and compliance materials instead of repeating the decline, and a clean research-use posture strengthens the application. A prior termination narrows the options and affects pricing, but it is not automatically disqualifying.

Not automatically, but a merchant account is never a judgment that your model is legal. These compounds are not FDA-approved for human use, and a research-use-only label does not by itself make a sale compliant; the FDA can still treat research chemicals sold to consumers as unapproved drugs. Underwriting prices the payment and dispute risk, not the legality of your business, which is on you and your counsel. A clean research-use posture with proper labeling and COAs is what keeps the payment side reviewable rather than an automatic decline.

Yes. Peptide, SARMs, and research-chemical sellers are accepted as US and international entities, including a US company with a foreign owner, and international merchants settle in their own currency where the rail supports it. A US owner with a US entity and an international owner are placed with different acquiring relationships, so the application asks which you are. The core materials reviewed are the same wherever the entity sits, meaning the labeling posture, certificates of analysis, marketing claims, and dispute profile, while the banking and settlement setup depends on the entity location and the rail.

No. There is no minimum monthly volume requirement for peptide merchant accounts, so a first-account seller with no processing history and an established brand moving real volume can both apply, each priced on its own file. A new seller is read on the storefront, the labeling, the certificates of analysis, and the bank and entity match rather than on statements it does not have yet.

Sometimes. A reserve is a percentage of volume the acquiring bank holds for a set window against future disputes, and it is common for newer high-risk accounts or those without processing history. Reserve-free options are available for some peptide merchants and categories, and where a reserve applies it is disclosed in writing before you sign, together with the rate and the settlement timing. A clean chargeback record is the case you can make for reducing or releasing it later.

Settlement timing depends on the rail and the merchant, and it is set out in writing before you sign rather than discovered on the first statement. What the timing is and whether a reserve applies are part of the written terms, and any later reduction of a reserve depends on the record you build, so a research-supply seller can plan cash flow around a schedule it has actually seen.